Skip to main content

Motor Neurone Disease

Question for Department of Health and Social Care

UIN 135354, tabled on 13 April 2018

To ask the Secretary of State for Health and Social Care, pursuant to his Oral Answer of 20 March 2018, Official Report, column 156, on motor neurone disease, which projects received that £52 million investment; and which 24 clinical trials are being recruited to.

Answered on

19 April 2018

In 2016-17, the National Institute for Health Research (NIHR) invested £52.2 million into health research covered by the ‘Neurological conditions’ category of the UK Health Research Classification System. This £52.2 million was used to fund and support a range of research studies and research infrastructure for neurological conditions and within that, £4.58 million was spent specifically on Motor Neurone Disease (MND) and closely-related conditions.

The NIHR provides the support, expertise and facilities that the NHS needs to undertake world-leading research funded by the NIHR, and other public, charity and life sciences industry partners, by funding a range of infrastructure facilities.

The NIHR Clinical Research Network is currently supporting 19 non-commercial studies and clinical trials on MND and closely-related conditions which are open and recruiting participants. The non-commercial studies are listed in the table below. There are currently two commercial studies which are also recruiting participants.

In 2016-17, the NIHR Research Infrastructure supported 23 studies and trials on MND and closely-related conditions in the NIHR Biomedical Research Centres, Units and other research infrastructure. The majority of these studies have been funded by research charities including the Motor Neurone Disease Association, other research funders and the life sciences industry.

NIHR Clinical Research Network supported Non-Commercial studies on MND and closely-related conditions which are open and recruiting participants

CPMS Study ID

Study Short Name

12497

Trajectories of Outcome in Neurological Conditions Phase 3 Consent and questionnaire

12495

Trajectories of Outcome in Neurological Conditions Phase 2 Demographics and Clinical Info

12768

Motor System Genomics, version 1.0

6160

ALS Biomarkers Study

35238

Tonic 2 Phase 4

20690

MND Register for England, Wales and Northern Ireland

12118

Trajectories of Outcome in Neurological Conditions Phase 1

13182

CSF collection in patients with neurodegenerative diseases

16242

BioMOx Phase 2: The Oxford Study for Biomarkers in Motor Neuron Disease

31877

A Multicentre Biomarker Study in Neurodegeneration

20372

Contributing clinical MRI scans to multi-centre collaboration

19128

Tongue EIM

17831

Using MRI to investigate energy metabolism in MND

34909

Improving support for family and friends caring for people with MND

35042

Serial fasciculation measurements in motor neurone disease

17557

Care Augmentation by Location-linked messaging CALL-Me

32678

MIROCALS_H2020/PHRC-N/2014/GB-01_ID-IL-2_Neuro-Inflammation in ALS Pts

36434

Change in MND

37175

ProSec 3